Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment
Rattachement africain : fi, ca, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: To investigate the association of adjuvant intraperitoneal (IP) and intravenous (IV) chemotherapy with location and timing of recurrence in patients with advanced high grade serous ovarian cancer (HGSOC). METHODS: This retrospective cohort study includes patients with stage III or IV HGSOC who underwent optimal primary cytoreductive surgery (PCS) and subsequently received paclitaxel and platinum-based chemotherapy, either IP or IV, at a tertiary care institution between 2010 and 2020. We performed adjusted multivariable logistic regressions to evaluate locations of first recurrence, and adjusted Cox proportional hazards models to assess the association of adjuvant chemotherapy administration and progression free survival. RESULTS: 208 patients met inclusion criteria, of whom 152 (73 %) received IP and 56 (27 %) received IV chemotherapy. IP chemotherapy was associated with decreased intraperitoneal recurrence (odds radio (OR) 0.33 (95 % confidence interval (CI) 0.17-0.64). Extraperitoneal disease at diagnosis was the only factor associated with increased extraperitoneal recurrence (OR 4.09 (95 % CI 1.84-9.10)). Presence of lymph node disease at diagnosis and gross residual disease at PCS were associated with increased lymph node recurrence (OR 4.54 (95 %CI 2.35-9.04) and OR 2.43 (95 %CI 1.18-5.11) respectively). After two years, the risk of recurrence was lower for patients who received IP, compared with IV, chemotherapy (HR 0.30 (95 % CI 0.17-0.53)). CONCLUSIONS: For patients with HGSOC after optimal PCS, IP chemotherapy is associated with decreased intraperitoneal recurrence and decreased risk of recurrence after 2 years compared with IV chemotherapy. This highlights its value in peritoneal restricted disease.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment
- Date Crossref
- 01/12/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Eastern Finland pays non établi dans la noticeUniversité ou école supérieure
-
University of Toronto Department of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
Sinai Health System pays non établi dans la noticeÉtablissement de santé
-
Brigham and Women's Hospital Massachusetts General Brigham pays non établi dans la noticeÉtablissement de santé
-
Dana-Farber Brigham Cancer Center pays non établi dans la noticeÉtablissement de santé
-
University Health Network pays non établi dans la noticeÉtablissement de santé
-
Princess Margaret Cancer Centre pays non établi dans la noticeÉtablissement de santé
-
Kuopio University Hospital Department of Obstetrics and Gynaecology pays non établi dans la noticeUniversité ou école supérieure
-
Dalla Lana School of Public Health pays non établi dans la noticeUniversité ou école supérieure
University of Eastern Finland, Department of Obstetrics and Gynecology — University of Toronto et Sinai Health System, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.